HC Wainwright reiterated their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research report sent to investors on Monday morning. HC Wainwright currently has a $20.00 target price on the biopharmaceutical company’s stock.
A number of other research analysts also recently issued reports on the company. Royal Bank Of Canada began coverage on Abeona Therapeutics in a report on Thursday, September 14th. They set an outperform rating and a $23.00 price target on the stock. Maxim Group set a $17.00 price target on Abeona Therapeutics and gave the company a buy rating in a report on Tuesday, August 29th. Zacks Investment Research downgraded Abeona Therapeutics from a hold rating to a sell rating in a report on Tuesday, August 22nd. BidaskClub downgraded Abeona Therapeutics from a buy rating to a hold rating in a report on Wednesday, August 2nd. Finally, Cantor Fitzgerald set a $21.00 price target on Abeona Therapeutics and gave the company a buy rating in a report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company has an average rating of Buy and an average target price of $18.50.
Shares of Abeona Therapeutics (ABEO) opened at 16.50 on Monday. The stock’s 50 day moving average price is $10.74 and its 200 day moving average price is $7.22. The stock’s market capitalization is $664.74 million. Abeona Therapeutics has a 12 month low of $4.05 and a 12 month high of $17.90.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.21 million. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. Analysts expect that Abeona Therapeutics will post ($0.68) EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in Abeona Therapeutics by 869.7% during the first quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock valued at $580,000 after acquiring an additional 104,038 shares during the last quarter. Family Management Corp purchased a new stake in Abeona Therapeutics during the first quarter valued at $120,000. Private Advisor Group LLC increased its position in Abeona Therapeutics by 50.0% during the first quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 6,999 shares during the last quarter. Wellington Management Group LLP increased its position in Abeona Therapeutics by 17.4% during the first quarter. Wellington Management Group LLP now owns 204,590 shares of the biopharmaceutical company’s stock valued at $1,023,000 after acquiring an additional 30,300 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new stake in Abeona Therapeutics during the second quarter valued at $594,000. Institutional investors own 38.24% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.